Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Therapeutics - Page 30

Therapeutics

American Cancer Society reported largest one-year drop in cancer mortality from 1991-2017
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics

American Cancer Society reported largest one-year drop in cancer mortality from 1991-2017

On Jan. 8, 2021, the American Cancer Society reported that the death rate from cancer in the U.S….

Read More American Cancer Society reported largest one-year drop in cancer mortality from 1991-2017Continue

In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutation
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutation

On Jan. 8, 2021, Pfizer and BioNTech announced results from an in vitro study conducted by Pfizer and…

Read More In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutationContinue

Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controls
Biotechnology | CDC | COVID-19 | Diagnostics | Infectious Disease | Influenza | Therapeutics

Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controls

On Jan. 7, 2021, Twist Bioscience announced it would supply the U.S. Centers for Disease Control and Prevention…

Read More Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controlsContinue

CytoDyn research on critically Ill COVID-19 patients published in Journal of Translational Autoimmunity
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

CytoDyn research on critically Ill COVID-19 patients published in Journal of Translational Autoimmunity

On Dec. 31, 2020, CytoDyn announced a research manuscript submitted by Nicholas J. Agresti, M.D. had been accepted…

Read More CytoDyn research on critically Ill COVID-19 patients published in Journal of Translational AutoimmunityContinue

Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccine
Biotechnology | COVID-19 | FDA | NIH | Therapeutics

Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccine

On Dec. 30, 2020, Medigen Vaccine Biologics announced that it had obtained TFDA Phase 2 IND approval of…

Read More Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccineContinue

Mateon global study for OT-101/ TGF-inhibitor against COVID-19 treated its first patient
Biotechnology | COVID-19 | Therapeutics

Mateon global study for OT-101/ TGF-inhibitor against COVID-19 treated its first patient

On Dec. 30, 2020, Mateon Therapeutics announced that it had enrolled and treated its first sentinel Part 1…

Read More Mateon global study for OT-101/ TGF-inhibitor against COVID-19 treated its first patientContinue

The Serum Institute of India launched India’s first indigenously developed pneumococcal vaccine
Biotechnology | Disease | Therapeutics | Vaccine

The Serum Institute of India launched India’s first indigenously developed pneumococcal vaccine

On Dec. 28, 2020, Serum Institute of India announced the launch of India’s first indigenously developed pneumococcal vaccine…

Read More The Serum Institute of India launched India’s first indigenously developed pneumococcal vaccineContinue

Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigen
Biotechnology | COVID-19 | FDA | Therapeutics

Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigen

On Dec. 22, 2020, Sorrento Therapeutics announced that an Emergency Use Authorization (EUA) Application had been submitted to…

Read More Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigenContinue

RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation

On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…

Read More RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendationContinue

Cocrystal Pharma selected lead compound for further development against Coronaviruses
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Cocrystal Pharma selected lead compound for further development against Coronaviruses

On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…

Read More Cocrystal Pharma selected lead compound for further development against CoronavirusesContinue

European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EU
Agriculture | Biotechnology | Diagnostics | Disease | Therapeutics

European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EU

On Dec. 21, 2020, Aimmune Therapeutics announced that the European Commission (EC) had approved PALFORZIA [defatted powder of…

Read More European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EUContinue

Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY

On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…

Read More Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATYContinue

FDA approved first adjuvant therapy for most common type of lung cancer
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics

FDA approved first adjuvant therapy for most common type of lung cancer

On Dec. 18, 2020, the the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Tagrisso (osimertinib) as the…

Read More FDA approved first adjuvant therapy for most common type of lung cancerContinue

National Research Council of Canada supported development of 4 COVID-19 therapeutic candidates
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

National Research Council of Canada supported development of 4 COVID-19 therapeutic candidates

On Dec. 18, 2020, the National Research Council of Canada (NRC) announced it was providing advisory services and…

Read More National Research Council of Canada supported development of 4 COVID-19 therapeutic candidatesContinue

Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico

On Dec. 18, 2020, Eli Lilly announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in…

Read More Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New MexicoContinue

RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model

On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…

Read More RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical modelContinue

Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testing
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testing

On Dec. 14, 2020, Anixa Biosciences announced that it and partner OntoChem GmbH had verified that one of…

Read More Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testingContinue

CIRM-funded project targeting sickle cell disease received green light for clinical trial
Biotechnology | CRISPR | FDA | Therapeutics

CIRM-funded project targeting sickle cell disease received green light for clinical trial

On Dec.14, 2020, the US Food and Drug Administration (FDA) announced they had granted Investigational New Drug (IND)…

Read More CIRM-funded project targeting sickle cell disease received green light for clinical trialContinue

Incyte announced results of phase 3 study of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 associated cytokine storm
Biotechnology | COVID-19 | Therapeutics

Incyte announced results of phase 3 study of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 associated cytokine storm

On Dec. 14, 2020, Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of…

Read More Incyte announced results of phase 3 study of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 associated cytokine stormContinue

AI test ruled out a COVID-19 diagnosis within one hour in Emergency Departments
Artificial Intelligence | Biology | COVID-19 | Infectious Disease | Therapeutics

AI test ruled out a COVID-19 diagnosis within one hour in Emergency Departments

On Dev. 11, 2020, the University of Oxford reported that an Artificial Intelligence test had been shown to…

Read More AI test ruled out a COVID-19 diagnosis within one hour in Emergency DepartmentsContinue

Data from ACTT-2 trial of Baricitinib in hospitalized COVID-19 patients supportive of the EUA published in NEJM
COVID-19 | FDA | Therapeutics

Data from ACTT-2 trial of Baricitinib in hospitalized COVID-19 patients supportive of the EUA published in NEJM

On Dec. 11, 2020, Eli Lilly and Incyte announced The New England Journal of Medicine had published the…

Read More Data from ACTT-2 trial of Baricitinib in hospitalized COVID-19 patients supportive of the EUA published in NEJMContinue

Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir
Biotechnology | COVID-19 | Nanotechnology | Therapeutics

Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir

On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy…

Read More Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivirContinue

High-dose influenza vaccine showed no additional benefit for heart disease patients
Biotechnology | Disease | Infectious Disease | Influenza | Therapeutics | Vaccine

High-dose influenza vaccine showed no additional benefit for heart disease patients

On Dec. 4, 2020, it was reported in JAMA that high-dose influenza (commonly known as flu) vaccines are…

Read More High-dose influenza vaccine showed no additional benefit for heart disease patientsContinue

US DoD awarded $25 million contract to Hollingsworth & Vose to increase production capacity of filtration media
COVID-19 | Medical Device | Therapeutics

US DoD awarded $25 million contract to Hollingsworth & Vose to increase production capacity of filtration media

On Dec. 3, 2020, the U.S. Department of Defense in coordination with the Department of HHS, awarded a…

Read More US DoD awarded $25 million contract to Hollingsworth & Vose to increase production capacity of filtration mediaContinue

University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific Impact
Biotechnology | Diagnostics | Disease | Medicine | Therapeutics

University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific Impact

On Dec. 2, 2020, the University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific…

Read More University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific ImpactContinue

Mateon announced development update for ARTIVEDA/ARTISHIELD against COVID-19
Biotechnology | COVID-19 | Therapeutics | WHO

Mateon announced development update for ARTIVEDA/ARTISHIELD against COVID-19

On Nov. 30, 2020, Mateon Therapeutics announced that the India arm of ARTI-19 global study was on track…

Read More Mateon announced development update for ARTIVEDA/ARTISHIELD against COVID-19Continue

Innovation Pharma’s COVID-19 clinical trial supported development of Brilacidin as ‘Pan-Coronavirus’ therapeutic
Biotechnology | COVID-19 | Therapeutics

Innovation Pharma’s COVID-19 clinical trial supported development of Brilacidin as ‘Pan-Coronavirus’ therapeutic

On Nov. 30, 2020, Innovation Pharmaceuticals announced additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin…

Read More Innovation Pharma’s COVID-19 clinical trial supported development of Brilacidin as ‘Pan-Coronavirus’ therapeuticContinue

RedHill Biopharma expanded U.S.-based manufacturing capacity of opaganib for COVID-19
Biotechnology | COVID-19 | Therapeutics

RedHill Biopharma expanded U.S.-based manufacturing capacity of opaganib for COVID-19

On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib….

Read More RedHill Biopharma expanded U.S.-based manufacturing capacity of opaganib for COVID-19Continue

BioNTech and InstaDeep announce AI Innovation Lab to develop novel immunotherapies
Artificial Intelligence | Biotechnology | Infectious Disease | Therapeutics

BioNTech and InstaDeep announce AI Innovation Lab to develop novel immunotherapies

On Nov. 25, 2020, BioNTech and InstaDeep announced a multi-year strategic collaboration aimed at applying the latest advances…

Read More BioNTech and InstaDeep announce AI Innovation Lab to develop novel immunotherapiesContinue

NeuroRx and Relief announced successful results from expanded use of RLF-100 in patients with COVID-19
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine

NeuroRx and Relief announced successful results from expanded use of RLF-100 in patients with COVID-19

On Nov. 24, 2020, RELIEF THERAPEUTICS announced that more than 175 patients with Critical COVID-19 and Respiratory Failure…

Read More NeuroRx and Relief announced successful results from expanded use of RLF-100 in patients with COVID-19Continue

Page navigation

Previous PagePrevious 1 … 28 29 30 31 32 … 106 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search